ArticleAmerican journal of translational research2019
Expression of IL-17 with tumor budding as a prognostic marker in oral squamous cell carcinoma.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Tumor Budding and Poor Prognosis in Oral Cancer: A Systematic Review and Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2023Pooled it
- Neutralizing dentin sialophosphoprotein facilitates tumor vascular normalization in colorectal cancer by blocking the crosstalk between tumor cells and endothelial cells.Acta pharmaceutica Sinica. B · 2026Article
- Unveiling Biomarkers in Head and Neck Squamous Cell Carcinoma through Bioinformatics: The Role ofInternational journal of molecular sciences · 2024Article
- The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies.Frontiers in immunology · 2024Review
- The IL-17 family in diseases: from bench to bedside.Signal transduction and targeted therapy · 2023Review
- T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment.International journal of molecular sciences · 2023Review
- The Role of IL-17 in the Pathogenesis of Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2023Review
- Tumour invasion and dissemination.Biochemical Society transactions · 2022Review
- The Role of Immune Modulatory Cytokines in the Tumor Microenvironments of Head and Neck Squamous Cell Carcinomas.Cancers · 2022Review
- Defining biomarkers in oral cancer according to smoking and drinking status.Frontiers in oncology · 2022Article
- MicroRNA‑198 suppresses tumour growth and metastasis in oral squamous cell carcinoma by targeting CDK4.International journal of oncology · 2021Article
- NRP2, a potential biomarker for oral squamous cell carcinoma.American journal of translational research · 2021Article
- Three-dimensional analysis of extrahepatic cholangiocarcinoma and tumor budding.The Journal of pathology · 2020Article
- Immunomodulatory aspects in the progression and treatment of oral malignancy.The Japanese dental science review · 2019Review
- Markers of Cancer Cell Invasion: Are They Good Enough?Journal of clinical medicine · 2019Review
- Tumor budding is a prognostic marker for overall survival and not for lymph node metastasis in Oral Squamous Cell Carcinoma - Systematic Review Update and Meta-Analysis.Journal of oral biology and craniofacial researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the relationship between IL-17 expression and tumor budding in the oral squamous cell carcinoma (OSCC) tumor invasion front (TIF). We also analyzed the correlation between OSCC prognosis and the co-expression of IL-17 and tumor budding. We obtained tumor tissues, tumor margins, and adjacent normal tissues from a total of 80 patients with OSCC. We measured IL-17 expression by ELISA and performed hematoxylin and eosin (H&E) and immunohistochemical staining to evaluate the presentation of tumor budding and IL-17 expression in the TIF. IL-17 expression was significantly increased in the tumor tissues and margins compared with that in the normal tissues, which was confirmed by immunohistochemical staining. There were correlations between IL-17-positive tumor budding and T classification, lymph node metastasis, distant metastasis, clinical stage, and recurrence. In a multivariate survival analysis, the IL-17-positive tumor budding, besides tumor budding alone, was highly correlated with prognosis. Our results demonstrate a positive relationship between IL-17 expression and tumor budding in the OSCC TIF. IL-17 combined with tumor budding can serve as a valuable predictor of prognosis for patients with OSCC.
Indexed as
Identifiers
30972211PMC6456524W2995571259What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.